🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 41% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

14 Gram(s) Serving Size
40 Servings
Other Combinations Product Type
41% Evidence Coverage

Supplement Facts — Evidence Check

Calories
Total Carbohydrates
15 mg (94% DV)
✅ 1.1× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 15mg UL 35mg
25 mg (1471% DV)
📊 19.2× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 25mg UL 100mg
680 mcg (170% DV)
✅ 1.7× RDA — within safe limits 📚 225 studies (Tier A: 10, B: 105)
RDA 0.4mg This product: 0.68mg UL 1.0mg
125 mcg (5208% DV)
📊 52.1× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.125mg
Sodium
100 mg (4% DV)
Timecop Performance Matrix
4000 mg
📊 Market median: 2000.0mg (275 products)
Median 2000.0mg This product: 4000mg
2000 mg
📊 Market median: 1500.0mg (104 products) 📚 21 studies (Tier A: 0, B: 2)
This product: 2000mg
1500 mg
📊 Market median: 500.0mg (223 products) 📚 22 studies (Tier A: 0, B: 1)
This product: 1500mg
📊 Market median: 496.0mg (192 products) 📚 20 studies — no high-quality reviews
This product: 1250mg
Agmatine Sulfate
750 mg
Lion's Mane
500 mg
✅ Within RDA (0.7× RDA of 550 mg) 📚 36 studies (Tier A: 1, B: 7)
RDA 550mg This product: 400mg UL 3500mg
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 375mg
VasoDrive-AP
254 mg
Theobromine
250 mg
Himalayan Pink Salt
250 mg
📊 Market median: 180.0mg (239 products) 📚 43 studies (Tier A: 1, B: 19)
This product: 200mg UL 400mg
Eria jarensis
200 mg
📊 Market median: 300.0mg (122 products) 📚 22 studies (Tier A: 0, B: 7)
This product: 150mg
📊 Market median: 180.0mg (239 products) 📚 43 studies (Tier A: 1, B: 19)
This product: 100mg UL 400mg
CoffeeBerry
50 mg
AstraGin
25 mg
Noopept
15 mg
Alpha Yohimbine
0.75 mg

Other Ingredients

Natural Flavors Citric Acid Silica Sucralose Acesulfame Potassium

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

⚠️ Warnings & Precautions

Warning! Extreme potency!

Allergen warning: Contains dairy.

🧪 Formulation Notes

Maximum focus Energy Strength

Peach Mango Natural flavors

AstraGin VasoDrive-AP Coffeeberry Coffee fruit solutions

Additional Information

Servings per container: 40/20

Product Details

DSLD Entry Date 2025-01-23
Product Type Other Combinations
Form Powder
DSLD ID 323741
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →